论文部分内容阅读
The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration,without secondary effects to healthy tissues.In order to remediate to this problem,we investigated if the conjugation of the polypropylenimine dendrimer to transferrin,whose receptors are overexpressed on numerous cancers,could result in a selective gene delivery to tumours after intravenous administration,leading to an increased therapeutic efficacy.